Vulvovaginal Candidiasis

Vulvovaginal Candidiasis (VVC) is an infectious disease, also known as ‘Vaginal thrush’, ‘monilia’, and vulvovaginal candidosis. VVC is usually caused by the yeast species Candida albicans, an infection of vagina associated with itchy rash of the vulva. Common symptoms include itching, soreness or burning discomfort in the vagina and vulva, heavy white curd-like vaginal discharge and bright red rash affecting inner and outer parts of the vulva, sometimes spreading widely in the groin to include pubic areas, inguinal areas and thighs.

As reported in many epidemiology based studies, the prevalence of VVC is highest among women in their reproductive years: 55 percent of female university students report having had at least one healthcare provider-diagnosed episode by age 25 years, 29 to 49 percent of premenopausal women report having had at least one lifetime episode, and 9 percent of women report having had four or more infections in a 12-month period (i.e., recurrent vulvovaginal candidiasis [RVVC]). In women with an initial infection, the probability of RVVC was 10 percent by age 25 years, and 25 percent by age 50 years.

Generic drugs are dominating the current therapeutic market for vaginal disease. Diflucan (fluconazole), a highly selective small molecule inhibitor of fungal cytochrome P450 C-14 alpha demethylase (CYP51) from Pfizer is the top-selling medication in the market. The major companies focused on the research and development of therapies for Vulvovaginal Candidiasis are Pfizer, Medinova, Bayer, Ferrer, Cidara Therapeutics, Scynexis, Viamet Pharmaceuticals and Matinas BioPharma. The pipeline drugs such as Arasertaconazole, CD101 Topical, SCY-078, and VT-1161 are few mid stage emerging therapies being evaluated for the treatment of VVC.

In a most recent event in January 2017, Cidara Therapeutics completed enrollment in phase 2 RADIANT trial evaluating novel antifungal CD101 topical in vulvovaginal candidiasis. Ferrer Internacional S.A. is also ready for the Phase III clinical trial development for the treatment of vulvovaginal candidiasis. There are many aspects that remain to be elucidated regarding the disease pathogenesis and clinical outcomes. The management of the disease is still a clinical challenge for scientific community due to unexplained aspects of the disease. There is a significant unmet medical need in the field of effective treatments with positive safety profile for better clinical outcomes.

 

Insight by:
Yuktie
Associate Analyst

DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating their decision-making. DelveInsight also serves as a knowledge partner for business strategy and market research. We provide comprehensive analytical reports across various therapeutic indications. DelveInsight has a database of 3000+ high-quality analytical reports.

Colony Stimulating Factor 1 Receptor (CSF1R): A key regulator of myeloid lineage cells

Colony Stimulating Factor 1 Receptor (CSF1R) is a cell-surface protein encoded, in humans, by the CSF1R gene. CSF1R is also known as macrophage colony-stimulating factor receptor (M-CSFR), and CD115 (Cluster of Differentiation 115), and is encoded by CSF1R gene which controls the production, differentiation, and function of macrophages. This receptor mediates most- if not all- of the biological effects of this cytokine. Clinically, mutations in CSF1R are associated with various types of leukemia such as chronic myelomonocytic leukemia and type M4 acute myeloblastic leukemia. Also, increased levels of CSF1R1 are found in microglia in Alzheimer’s disease and after brain injuries. It is also believed to have a role in the process of mammary gland carcinogenesis. Mutations in the tyrosine kinase domain have been associated with hereditary diffuse leukoencephalopathy with spheroids.

A study conducted by Jian Luo et al. demonstrates that the systemic administration of human recombinant CSF1 ameliorates memory deficits in a transgenic mouse model of Alzheimer’s disease. Colony Stimulating Factors (CSF) has also role in inflammatory responses. It helps in synergizing the attracting capabilities of chemokines and of inducing the accumulation and/or activation key components of inflammatory responses. Researchers are developing various therapeutic candidates in the form of small molecule as well as monoclonal antibodies mainly for the treatment of cancers and inflammatory diseases. These drugs are being evaluated as monotherapy and/or combination therapy.

Major companies involved in the development of the CSF1R antagonists includes Eli Lilly and Company, Hoffmann-La Roche Novartis Pharmaceuticals, Pfizer, Daiichi Sankyo, Amgen and many other. Plexxikon (A member of the Daiichi Sankyo Group) has three products in its pipeline, including Pexidartinib in Phase III stage of development for the treatment of Tenosynovial Giant Cell Tumor (TGCT), Pigmented villonodular synovitis (PVNS), Giant cell tumors of the tendon sheath (GCT-TS), Glioblastoma and Melanoma. PLX7486 and PLX 73086 are currently in Phase I stage of development for the treatment of Pancreatic and Solid Tumors and Tenosynovial Giant Cell Tumor (TGCT), respectively. BCI Pharma has its two therapeutic candidates (Dual flt3-CSF1R kinase inhibitor and Selective CSF1R kinase inhibitor) in pipeline, currently in discovery stage of development.

Pexidartinib (Plexxikon), AB 1010 (AB Science SA), FPA-008 (Five Prime Therapeutics, Inc.) and SB1518 (CTI BioPharma) have been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (USFDA) and/or the European Medicines Agency (EMA) for different indications. More than 10 different types of collaboration agreement between different pharmaceutical and biotechnology companies and research institutes for the development of CSF1R antagonist makes it an interesting and promising target mainly for the Immuno-Oncology drugs, and has provided hope to meet the challenges of treating these diseases.

Insight by:
Mohammad Rizwan
Associate Analyst

DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating their decision-making. DelveInsight also serves as a knowledge partner for business strategy and market research. We provide comprehensive analytical reports across various therapeutic indications. DelveInsight has a database of 3000+ high-quality analytical reports.

The Business Cocktail

PMV Pharma Raises $74M, Aiming to Hit Cancer’s Hard Target- P53

PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The company raised a $74 million Series B round from Topspin Biotech Fund, Euclidian Capital, InterWest Partners, OrbiMed Advisors, and Osage University Partners. PMV raised a $30 million Series A in 2014. The new cash will help PMV push into human clinical studies, though in its statement the startup didn’t say when those studies might begin. Like many of its peers, PMV wants to restore the function of mutated p53 with a drug, though it didn’t disclose exactly what its approach will be.

Argos Shares Plummet following Reports of Failed Results for Kidney Cancer Therapy

An Argos Therapeutics therapy that uses the immune system to fight kidney cancer has hit a wall after an analysis of the latest clinical trial data found that the experimental treatment was unlikely to work. Following the planned interim analysis of Argos’s Phase 3 clinical trial, the independent data monitoring committee recommended stopping the study for futility, the company announced this morning. Shares in Durham, NC-based Argos plummeted more than 62 percent to $1.65 on the news. Argos said that it is analyzing the preliminary data from the clinical trial and it plans to discuss that information with the FDA. In the meantime, Argos said that it plans to leave the clinical trial open.

Cidara Antifungal Flunks in Phase 2 Clinical Trial, Shares Sink

Cidara Therapeutics is halting work on an experimental topical antifungal drug designed to treat vaginal yeast infections after the compound wasn’t better than the current standard of care in a Phase 2 clinical trial. Investors frowned on the news, sending the company’s shares down more than 38 percent to $7.24 on 21st morning. Cidara is turning its attention to CD101 IV, which is in a Phase 2 trial for the fungal infection candidemia. Results for that clinical trial are expected in the fourth quarter. Cidara will also continue working on CD201, a potential treatment for infections caused by drug-resistant Gram-negative bacteria.

Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead for $125M

Sarepta Therapeutics didn’t just get its first drug to market when the FDA approved the Duchenne muscular dystrophy drug eteplirsen (Exondys 51) last year—it got a potentially lucrative voucher from the FDA too. Sarepta sold the priority review voucher to Gilead Sciences in a deal worth $125 million. Sarepta will use the cash to help develop next-gen drugs for Duchenne. Priority review vouchers are awarded to companies that bring treatments to market for neglected tropical diseases and rare pediatric ailments, enabling a swifter review from the FDA, and potentially adding millions in revenue for a company, or giving a drugmaker a leg up over a competitor with a rival therapy.

Novartis and NHS Ayrshire & Arran launch new eye care facility in Scotland

Novartis Pharmaceuticals UK and NHS Ayrshire & Arran have announced the launch of a new facility designed specifically for people suffering from some of the most common forms of avoidable sight loss. The facility is set to support the delivery of a one-stop clinic for patients and is expected to transform the patients’ eye service by building an extension on to the existing Ophthalmology Outpatient Department.

The Snippet: Delay in hiring science advisers intensifies Brexit worries

Two government departments charged with managing the United Kingdom’s departure from the European Union have not yet appointed chief scientific advisers (CSAs) — and might not do so. That is starting to concern science-policy experts, who worry that scientists won’t be at the table when government makes key decisions on issues such as environmental protection and membership of international collaborations. The United Kingdom has for years embraced the CSA model, in which highly qualified researchers are appointed to senior advisory roles and then embedded in government departments. But neither the Department for Exiting the European Union (DExEU) nor the Department for International Trade (DIT), both of which were created in the wake of the United Kingdom’s decision to leave the EU, has yet appointed, or committed to appointing, a CSA.

To know more, click here.

Familial Adenomatous Polyposis (FAP): A cataclysmic genetic mutation

Familial Adenomatous Polyposis (FAP) results from a germ line mutation in the Adenomatous Polyposis Coli (APC) gene. FAP is an autosomal dominantly inherited disorder, which is characterized by the formation of numerous colorectal adenomatous polyps and leads to the cancer of the large intestine (colon) and rectum. The mutation in the APC affects the ability of the cell to maintain normal growth and function. Cell overgrowth resulting from mutations causes complications in the form of colon and rectum cancer.

The incidence of FAP, as reported in many epidemiology based reports varies from 1 in 7,000 to 1 in 22,000 individuals. About 30% of people with FAP do not have any family history of the condition; they have a de novo (new) mutation in the APC gene. Males and Females are equally affected (1:1) by FAP and reported in all races. The average age of onset of polyposis in FAP is 16 (range 7-36 years) years, whereas by age 35 years, 95% of individuals with FAP have polyps; without colectomy, colon cancer is unavoidable.

In January 2017, Marina Biotech was granted European claims covering Bacteria Mediated Gene Silencing (EP 08768475.9, European Patent 2173875), which claims the company’s tkRNAi technology being utilized in its CEQ508 program that is being developed to treat FAP. Previously in 2015, the U.S. Food and Drug Administration (FDA) have granted Fast Track designation to CEQ508, for the treatment of FAP. There are around 7 drugs in pipeline being investigated in different stage of development for FAP. A few projects for FAP, such as development of Ursodeoxycholic by Aptalis have been put on hold (dormant) due to some undisclosed reasons. Whereas, the development of Exisulind by OSI Pharmaceuticals and Valproic acid by Onxeo SA has now been discontinued.

Despite rigorous investigation by researchers to develop a reliable therapeutic to treat patients with FAP, there remains significant unmet medical needs. The long-term and frequent assessment and interventions even after radical colectomy, represent one of the major unmet medical needs. Modest Efficacy measured by reduction in the number (and size) of polyps demonstrated with current therapies is also a matter of concern for the researchers that needs to be addressed soon.

Insight by:
Mohammad Rizwan
Associate Analyst

DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating their decision-making. DelveInsight also serves as a knowledge partner for business strategy and market research. We provide comprehensive analytical reports across various therapeutic indications. DelveInsight has a database of 3000+ high-quality analytical reports.

The Business Cocktail

AMRI enters alliance with Bruker Daltonics and HighRes Biosolutions

AMRI has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high throughput mass spectrometry (MS) for drug discovery. AMRI has acquired the new MALDI PharmaPulse system from Bruker Daltonics and HighRes Biosolutions. The system will be deployed at AMRI’s Integrated Drug Discovery Center and, in accordance with the terms of the alliance, Bruker Daltonics and HighRes Biosolutions will provide training and consulting to AMRI biologists to aid them in their development of protocols on the system that can be used for high throughput screening drug discovery programs.

Ferring Pharmaceuticals and Enteris BioPharma enter into a license agreement

Ferring Pharmaceuticals and Enteris BioPharma have entered into a license agreement and initiated an early development agreement to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence, to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring. Enteris will license to Ferring its oral drug delivery technologies, as well as provide clinical trial finished product, and will receive milestones and royalties based on net sales of the developed product.

Quotient Clinical Acquires SeaView Research

Quotient Clinical has acquired SeaView Research with the aim of expanding its operations into the U.S. The acquisition combines Quotient and SeaView’s complementary customer portfolios, and strengthens the early phase clinical experience of the combined business, enabling the company to deliver a broader set of services. Each of the facilities is capable of undertaking complex clinical research studies including first-in-human investigations.

Renova takes over Rights of stresscopin from Janssen

Renova Therapeutics, gene therapy specialist, has signed an agreement to receive the investigational new drug (IND) file for stresscopin from Janssen Pharmaceuticals. Stresscopin is a hormone involved in responses to physiological stress and was previously under development at Janssen. Stresscopin has been shown in preclinical studies to protect cells exposed to fluctuating oxygen levels, such as occur in the heart in cardiovascular disease. Janssen’s scientists had previously shown that stresscopin and other related peptides can increase the ability of heart cells to contract. Renova will advance the programme development as RT-400, a peptide infusion treatment for episodes of acute decompensated heart failure (ADHF), which accounts for about half of all heart failure-related causes of hospitalization in the US.

The Business Cocktail

ALCMI, ALCF and Scancell partner to evaluate SCIB2 cancer vaccine for NSCLC

The Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J. Addario Lung Cancer Foundation (ALCF) have collaborated with UK-based Scancell to assess SCIB2 cancer vaccine to treat patients with non-small-cell lung cancer (NSCLC). SCIB2 is Scancell’s second ImmunoBody cancer vaccine platform currently under development. It stimulates the immune system to potentially treat and prevent cancer. Scancell has successfully completed a Phase I / II clinical trial with SCIB1 cancer vaccine by using it on patients suffering from melanoma. Along with having the ability to complement existing treatments, SCIB2 can also work in cases where current treatments either do not work or are not available.

Sun looks to unload Ohm Labs New Jersey plants in manufacturing consolidation

The Indian company is reportedly looking to sell New Jersey plants as part of a manufacturing consolidation. The facilities have been on the market for a couple of months and are expected to fetch about $100 million. Sun Pharma got the solid-dose, prescription and OTC manufacturing facilities in its 2015 buyout of Ranbaxy Laboratories, and is slimming down its manufacturing operations since the buyout, last year selling plants in Philadelphia, Pennsylvania, and Aurora, Illinois, to CDMO Frontida BioPharm. Before that, it struck a deal to sell a formulation plant in Bryan, Ohio, to Nostrum Laboratories, a Kansas City, MO-based generics maker, and announced the closure of a plant in Tipperary, Ireland.

Takeda and Ovid join forces to co-develop Drug for Rare Pediatric Epilepsies

In January 2017, Takeda and Ovid Therapeutics announced an agreement to co-develop a drug for rare pediatric epilepsies. Takeda’s compound, TAK-935, is at the heart of this agreement, with its continued development and commercialization in the US, Europe, Canada, and Israel being conducted by Ovid. Takeda will be developing the drug in Japan and other Asian markets. This unusual agreement also allows the companies to share the development and commercialization costs 50/50, and in the event of a successful launch to share profits equally as well.

Guardant and MD Anderson collaborate for liquid biopsy deal

Guardant Health and the University of Texas MD Anderson Cancer Center have struck a multiyear deal to push comprehensive liquid biopsy into the standard of care in cancer treatment. The commercial, research and development agreement will see Guardant helping MD Anderson build multiple liquid biopsy centers on site, according to a statement. The company launched its Guardant360 test in 2014 and says it is the most validated and sensitive liquid biopsy on the market.

Glooko and Ascensia integrate their offerings to boost diabetes management

In its second partnership announced this month, Glooko is teaming with Ascensia Diabetes Care to connect the latter’s blood glucose monitoring systems to its diabetes data management platform. Under the partnership, the pair will integrate Ascensia’s Contour Next One and Contour Plus One systems into Glooko’s platform. The goal is to improve diabetes data management and analytics for patients and physicians. Earlier this month, Glooko and Novo Nordisk joined forces to develop “digital health solutions” for diabetes management.

 

The Business Cocktail

Payers block Kaléo’s expensive EpiPen challenger

Kaléo reintroduced its Auvi-Q last week at a list price of $4,500 for a two-pack in an effort to capture some market share from Mylan’s EpiPen, which is listed at about $600 for a two-pack. Auvi-Q is set to launch next month. Under Kaléo’s pricing strategy, Auvi-Q will cost most patients $0 out-of-pocket. If an insurer refuses to cover the med, the company will step in and pay for that access, execs said last week. Uninsured patients can purchase the drug at a cash price of $360 for a two-pack. Instead, the strategy shifts the costs to insurers and pharmacy benefit managers. At a list price multiples higher than its competition, Kaléo Pharma’s revived Auvi-Q has hit resistance from some of the nation’s top pharmacy benefit managers and insurers. Cigna has said no to the idea, while Humana is not talking to the company and Aetna is restricting its product for now.

FTC settlement clears Endo from pay-for-delay liability; Watson, Allergan charged

According to the FTC complaint, Lidoderm was an important product for Endo back in 2011. That year, the company made $825 million in sales off the lidocaine patch, or 30% of its annual sales haul, meaning generic competition would pose “significant financial risks” to the company. Endo paid Watson at least $250 million to delay that competition, according to the feds. Through an “administrative complaint,” authorities are also going after Impax Laboratories, which they say received $112 million back in 2010 to delay a generic competitor to Endo’s Opana ER. Endo International has pledged to swear off pay-for-delay agreements. But even as the government moves to wrap up its case against Endo, authorities continue to pursue claims against Watson and Allergan.

Amgen hikes prices by single digits, with Enbrel matching AbbVie’s Humira boost

Amgen raised the price of its top-selling med, Enbrel, an 8.4% hike that followed a larger one just six months ago. It also came on the heels of an identical price hike for one of Enbrel’s key competitors, AbbVie’s Humira. Amgen executives say payer discounts will eat up most if not all of its latest hikes. The move follows a 28% increase for the anti-TNF blockbuster in 2015 and another boost of 9.9% in July 2016. During Amgen’s third-quarter 2016 conference call, commercial operations head Anthony Hooper said the company expects “relatively little benefit” on Amgen price changes in 2017 due to competitive payer negotiations.

Baxter paying $18M to settle federal case over sterile plant failings

Ignoring issues in a sterile manufacturing plant can lead to big problems, like FDA warning letters, which Baxter International received for a plant in North Carolina after mold was found in HEPA filters. But in rare cases, it can lead to even more severe penalties, like the $18 million-plus Baxter will pay to resolve a federal criminal case, as well as a civil matter brought by a whistleblower over the mold concerns.  Baxter will pay another $2.158 million to resolve a civil whistleblower case brought by Baxter employee Christopher Wall who had reported to the mold problem to plant management. Wall’s case alleged his concerns were overlooked and the plant continued to manufacture and sell product from the facility. Wall gets $431,535.99 as his share of the settlement.

Notizia

U.K. weighs drug rationing as NHS England’s budget tightens: report

Patients in the U.K. face yet another barrier to access as a tough budget situation has forced the country’s healthcare system to consider rationing costly drugs. Among them are medicines from Johnson & Johnson, Merck and Roche. Beginning in April, cancer patients and others could have to line up for medicines that cost NHS England more than £20 million per year, The Times reported. That’s even after those meds have been deemed cost-effective by the National Institute for Health and Care Excellence (NICE). The move comes at a troublesome time at NHS, as its chief executive, Simon Stevens, said publicly this month that Prime Minister Theresa May was “stretching the truth” about the agency’s budget. He said NHS received “less than we asked for” from the British government.

Applying Digital Technologies to Profit from Change in the Pharma Industry

Pharmaceutical companies are increasingly challenged to keep pace with the evolving demands of patients, physicians and payers. Patients are increasingly seeking higher levels of involvement and understanding of their own treatment plans. In fact, a recent survey found that more than 85% of patients are confident in their ability to take responsibility for their health and knew where to access online resources to do so. Much of this information is sought after via mobile devices: over 60% of smartphone users use their mobile devices to search for information regarding a health condition. Furthermore, patients are increasingly favoring third party sites where they can obtain syndicated information on health conditions and related treatments.

Drugmakers ‘hijacked’ the FDA’s orphan system to score premium pricing on mass-market meds

There’s no denying that financial incentives for orphan drug development saved hundreds of thousands of lives. But they’ve also helped mass-market drug makers rack up millions in incentives, tax breaks and patent-protected profit. According to a report, About one-third of the orphan drug approvals since the program began have been for repurposed, large-market products or drugs with multiple orphan green lights. Best-sellers such as Crestor from AstraZeneca, Abilify from Otsuka, Herceptin from Roche and Humira from AbbVie fall into the category of big sellers whose makers snagged millions in government incentives—not to mention seven years of exclusive rights on the market—when they resubmitted their therapies as treatments for smaller populations. Others, such as Allergan blockbuster Botox, started out as small-market meds and proceeded to collect multiple orphan approvals.

FDA slaps Florida blow-seal-fill facility with warning letter

The FDA has come down on an aseptic blow-fill-seal pharma manufacturing operating in Florida that the agency says has widespread issues with microbiological contamination. The FDA posted a warning letter that was issued last month to Horizon Pharmaceuticals following an inspection that dates back to the fall of 2015. The FDA said that when it inspected the company’s facility in Riviera Beach, Florida, it “found multiple deficient practices at (the) facility that pose a significant microbiological contamination risk.” Among those was its cleaning and disinfection program, which it said didn’t use a sporicidal agent. The inspectors discovered the facility had shipped three lots of an ophthalmic drug even though some bottles which were tested were contaminated with Bacillus mycoides, which is a spore-forming microbe.

Cytomegalovirus (CMV) infection: Market Outlook

Cytomegalovirus (CMV) infection is a major Herpes virus infection, which is the leading cause of morbidity and mortality worldwide among congenitally infected newborns, HIV/AIDS patients and transplant recipients. According to Centers for Disease Control and Prevention, approximately 80,000 cases of CMV infections are found in United States and Europe. High prevalence of Cytomegalovirus (CMV) infection is found in developing countries and in areas of lower socioeconomic conditions.

In terms of treatment scenario, several drugs such as Valganciclovir (Valcyte), Foscarnet (Foscavir), Cidofovir (Vistide) are approved and marketed. Valtrex and Cytotect are approved for Cytomegalovirus (CMV) infection, and Valganciclovir or Ganciclovir are used as first-line treatment. Additionally, Foscavir is used as second-line therapy for patients who do not respond to Ganciclovir treatment. Lastly, Cidofovir is used as an alternative therapy among those patients who do not respond to Ganciclovir and Foscarnet treatment. The current market of CMV infection is weak due to presence of several generics, such as Ganciclovir and Foscarnet, and patent expiry of marketed drugs.

Due to increasing awareness related to herpes virus infections, improvement in healthcare infrastructure, increase in number of patients undergoing transplantation, government support and increase in prevalence of CMV infection, there is a hope for the Global market size of CMV infection to increase from USD 698.3 Million in 2013 to USD 1,210.4 Million by end of year 2023. Prophylactic and therapeutic market size is expected to grow at a CAGR of 6.57% and 3.44% respectively, during 2013-2023. Major players such as Merck & Co., Chimerix Inc, Astellas Pharma and CSL Behring are developing drugs which are expected to be launched in coming years. These emerging therapies have better efficacy and safety profiles as compared to the existing therapies. Launch of emerging therapies such as Letermovir and TransVax in coming years may also stimulate growth of the CMV market. Also, companies are focusing on developing drugs with novel mechanisms of action beyond DNA polymerase inhibitors, which may provide a stiff competition to the existing therapies.

Insight by:
Diksha Wadhwa
Associate Analyst

DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business and facilitating their decision-making. DelveInsight also serves as a knowledge partner for business strategy and market research. We provide comprehensive analytical reports across various therapeutical indications. Delveinsight has a database of 3000+ high-quality analytical reports.